|Articles|March 24, 2015

PHT Adopts Vodafone M2M Tech

Author(s)Applied Clinical Trials Editorial Staff

Vodafone’s Machine-to-Machine (M2M) technology enables PHT Corporation to more efficiently manage worldwide clinical trials through real-time access to patient experience data

Vodafone and PHT Corporation, a provider of technologies used to collect electronic data for clinical research from patients, will connect the PHT electronic clinical outcome assessment (eCOA) system to Vodafone’s global M2M network. Using Vodafone’s global M2M network, PHT can provide pharmaceutical trial sponsors real-time access to patient data. Currently the PHT eCOA System is used to collect data in clinical trials in more than 75 countries.

Read the full release here.

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Related to this article

October 17th, 2026

2026 SCRS Global Site Solutions Summit: Should the Industry Rethink What Scale Means?

Paradigm’s Kurt Mussina discusses why scale should drive operational efficiency, not consolidation into single-site studies.

October 17th, 2026

2026 SCRS Global Site Solutions Summit: The Difference Between Owning a Group of Sites and Operating Them as One Integrated Platform

Paradigm’s Kurt Mussina touches on why he rejects the “site management organization” model in favor of one unified business.

October 17th, 2026

2026 SCRS Global Site Solutions Summit: What's a Mistake Sponsors or CROs Make When Rolling Out New Trial Technology?

ProofPilot’s Lauren Briggs talks on why sponsors and CROs fail at tech rollouts by skipping change management, and pushes for the industry to judge trial technology by real workflow impact rather than feature checklists.

October 17th, 2026

2026 SCRS Global Site Solutions Summit: What Causes Technology Adoption to Stall?

ProofPilot’s Lauren Briggs touches on why site tech adoption hinges on the first 90 days after rollout, and why tools succeed only when they remove work from a site’s plate rather than adding another login to juggle.

October 17th, 2026

2026 SCRS Global Site Solutions Summit: What's the Biggest Policy Gap Delaying Integrated, Community-Based Research Being the Norm?

Jennifer Byrne, CEO, Javara touches on why fixing clinical research requires sustained infrastructure investment and workforce development.

Dan White, CEO, and Dr. Tom Kreamer, CMO

October 17th, 2026

2026 SCRS Global Site Solutions Summit: What Should Sponsors and CROs Change About How They Contract with a Network?

Sequoia’s Dan White and Dr. Tom Kreamer touch on why sponsors and CROs should treat a site network as one centralized partnerto speed startup timelines and strengthen execution.

October 17th, 2026

2026 SCRS Global Site Solutions Summit: What Does it Take to Turn Three Independent Site Organizations into One Functioning Network?

Sequoia Clinical Research’s CEO Dan White and CMO, Dr. Tom Kreamer explain what it takes to merge three site organizations into one network.

October 17th, 2026

2026 SCRS Global Site Solutions Summit: What Does Embedding Research into Existing Physician Practices Require?

Javara CEO Jennifer Byrne talks about the requirements for embedding clinical trials directly into physician practices and why solving the “last mile” of trial participation means building infrastructure at the actual point of care.